OSUR Earnings Prediction
The chart below shows how OSUR performed 10 days before and after its earnings report, based on data from the past quarters. Typically, OSUR sees a +1.77% change in stock price 10 days leading up to the earnings, and a +9.03% change 10 days following the report. On the earnings day itself, the stock moves by -1.00%. This data can give you a slight idea of what to expect for the next quarter's release.
OSUR Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
39.91M
-55.25%
-26.54%
Gross Margin
42.77%
-13.98%
-5.88%
Operating Margin
-15.03%
-178.69%
384.84%
Net Margin
-11.29%
-190.25%
899.12%
EPS
-0.06
-140.00%
500.00%
No Data Available
OSUR Earnings Analysis
OraSure Technologies Inc Corporation (OSUR.O) Earnings Conference Call
Positive
Strong Revenue Performance: In Q3, total revenue was $39.9 million, with core revenue of $37.8 million, indicating strong performance.
International HIV Revenue Growth: Core revenue generated $22 million in Q3, increasing by 13% year-over-year, driven by strong order trends in the international HIV business.
Strong Operational Cash Flow: Operating cash flow for Q3 was $12.7 million, reflecting solid operational performance in the core business.
Strong Balance Sheet: The company ended Q3 with zero debt and total cash and cash equivalents of $279 million, showcasing a healthy balance sheet.
Gross Margin Consistency: GAAP gross margin in Q3 was 42.8%, consistent with expectations, indicating effective cost management.
Negative
Core Revenue Decline: Core revenue decreased 1% year-over-year in Q3, impacted by a decrease in revenue from the risk assessment testing business that we are exiting.
Q3 Revenue Decline: Sample management revenue in Q3 was $12.8 million, a decrease of 16% year-over-year, despite an increase on a sequential basis for the second consecutive quarter.
Operating Loss Comparison: GAAP operating loss in Q3 was $6 million, while non-GAAP operating loss was $2.7 million.
Core Revenue Decline: Core revenue, excluding COVID-19 products, was $37.8 million, indicating a decline in overall revenue performance.
Revenue Decline in Testing: The risk assessment testing business generated revenues of $1.9 million in Q3, a decline from $2.6 million in Q3'23.
OSUR FAQs
How does OSUR typically perform around its earnings report dates?
Is OraSure Technologies, Inc. (OSUR) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
OSUR Earning Call Sentiment
OraSure Technologies, Inc. (OSUR) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
OSUR.O
1.03%Positive
The earnings call summary presents a mixed outlook. While there are positive developments like the WHO prequalification for new products and a strong international HIV business, there are significant challenges such as competitive pressures, economic factors impacting revenue, and operational risks. The Q&A section highlights uncertainties, especially regarding margin improvements and partnerships. The financial performance shows slight declines in revenue and operating losses, offset by a solid cash position. Given these mixed factors, the stock price is likely to remain stable, resulting in a neutral prediction (-2% to 2%).